Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019

Jianghong Fan; Xinyuan Zhang; Jiang Liu; Yuching Yang; Nan Zheng; Qi Liu; Kimberly Bergman; Kellie Reynolds; Shiew-Mei Huang; Hao Zhu; Yaning Wang

doi:10.1093/cid/ciaa623

Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019

Clin Infect Dis. 2020 Dec 15;71(12):3232-3236. doi: 10.1093/cid/ciaa623.

Authors

Affiliations

¹ Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
² Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
³ Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Abstract

Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.

Keywords: COVID-19; SARS-CoV-2; antiviral activity; hydroxychloroquine.

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

MeSH terms

Antiviral Agents* / therapeutic use
COVID-19 Drug Treatment*
Humans
Hydroxychloroquine*
SARS-CoV-2

Substances

Antiviral Agents
Hydroxychloroquine